These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33014831)

  • 81. Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas.
    Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
    Cancer Cell; 2023 Jun; 41(6):1198. PubMed ID: 37311416
    [No Abstract]   [Full Text] [Related]  

  • 82. Correction:
    Gut; 2021 Oct; 70(10):e7. PubMed ID: 34497120
    [No Abstract]   [Full Text] [Related]  

  • 83. Correction: Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
    Yu F; Li L; Zhang M; Sun S
    BMC Cancer; 2023 Dec; 23(1):1176. PubMed ID: 38041002
    [No Abstract]   [Full Text] [Related]  

  • 84. Author Correction: EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma.
    Liu H; Liu Y; Liu W; Zhang W; Xu J
    Nat Commun; 2021 Nov; 12(1):6487. PubMed ID: 34741007
    [No Abstract]   [Full Text] [Related]  

  • 85. Retraction Note: Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelialmesenchymal transition, migration, and on the pro-inflammatory phenotype.
    Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
    Clin Epigenetics; 2023 Nov; 15(1):179. PubMed ID: 37936214
    [No Abstract]   [Full Text] [Related]  

  • 86. Correction: EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis.
    Guan X; Deng H; Choi UL; Li Z; Yang Y; Zeng J; Liu Y; Zhang X; Li G
    Oncogene; 2023 Jan; 42(1):78. PubMed ID: 36443397
    [No Abstract]   [Full Text] [Related]  

  • 87. Regulation 33B in Practice.
    Br Med J; 1944 Feb; 1(4336):223-4. PubMed ID: 20785280
    [No Abstract]   [Full Text] [Related]  

  • 88. Statistics of cases reported under Regulation 33B.
    Br J Vener Dis; 1944 Mar; 20(1):30. PubMed ID: 21773378
    [No Abstract]   [Full Text] [Related]  

  • 89. THE COMPULSORY TREATMENT OF VENEREAL DISEASES UNDER REGULATION 33B.
    Shannon NP
    Br J Vener Dis; 1943 Jun; 19(2):67-77. PubMed ID: 21773350
    [No Abstract]   [Full Text] [Related]  

  • 90. THE COMPULSORY TREATMENT OF VENEREAL DISEASES UNDER REGULATION 33B.
    Shannon NP
    Br J Vener Dis; 1943 Mar; 19(1):22-33. PubMed ID: 21773339
    [No Abstract]   [Full Text] [Related]  

  • 91. RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.
    Sánchez-Molina S; Figuerola-Bou E; Blanco E; Sánchez-Jiménez M; Táboas P; Gómez S; Ballaré C; García-Domínguez DJ; Prada E; Hontecillas-Prieto L; M Carcaboso Á; Tirado ÓM; Hernández-Muñoz I; de Álava E; Lavarino C; Di Croce L; Mora J
    Sci Adv; 2020 Oct; 6(43):. PubMed ID: 33097530
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
    Li Y; Vennapusa B; Chang CW; Tran D; Nakamura R; Sumiyoshi T; Hegde P; Molinero L
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):258-264. PubMed ID: 33030848
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.
    Blanco-Gómez A; Hontecillas-Prieto L; Corchado-Cobos R; García-Sancha N; Salvador N; Castellanos-Martín A; Sáez-Freire MDM; Mendiburu-Eliçabe M; Alonso-López D; De Las Rivas J; Lorente M; García-Casas A; Del Carmen S; Abad-Hernández MDM; Cruz-Hernández JJ; Rodríguez-Sánchez CA; Claros-Ampuero J; García-Cenador B; García-Criado J; Orimo A; Gridley T; Pérez-Losada J; Castillo-Lluva S
    Cancer Res; 2020 Dec; 80(23):5216-5230. PubMed ID: 33023950
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Tesch ME; Gelmon KA
    Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer.
    Gautam SK; Kanchan RK; Siddiqui JA; Maurya SK; Rauth S; Perumal N; Atri P; Venkata RC; Mallya K; Mirza S; Ponnusamy MP; Band V; Mahapatra S; Jain M; Batra SK; Nasser MW
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33019652
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Critical regulation of a NDIME/MEF2C axis in embryonic stem cell neural differentiation and autism.
    Bai M; Ye D; Guo X; Xi J; Liu N; Wu Y; Jia W; Wang G; Chen W; Li G; Jiapaer Z; Kang J
    EMBO Rep; 2020 Nov; 21(11):e50283. PubMed ID: 33016573
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 98.
    Williams EA; Sharaf R; Decker B; Werth AJ; Toma H; Montesion M; Sokol ES; Pavlick DC; Shah N; Williams KJ; Venstrom JM; Alexander BM; Ross JS; Albacker LA; Lin DI; Ramkissoon SH; Elvin JA
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33015533
    [TBL] [Abstract][Full Text] [Related]  

  • 99.
    Li C; Ge M; Chen D; Sun T; Jiang H; Xie Y; Lu H; Zhang B; Han L; Chen J; Zhu J
    Front Oncol; 2020; 10():1730. PubMed ID: 33014855
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.
    Garrido-Cano I; Constâncio V; Adam-Artigues A; Lameirinhas A; Simón S; Ortega B; Martínez MT; Hernando C; Bermejo B; Lluch A; Lopes P; Henrique R; Jerónimo C; Cejalvo JM; Eroles P
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.